Mando Group AB has developed a non-invasive treatment for eating disorders and obesity that is based on 25 years of clinical research in collaboration with the Karolinska Institute in Stockholm. Using the Mandometer® medical device allows patients to learn how to eat normally and when to feel full.
The treatment is based on scientific evidence obtained in randomized controlled clinical trials, which demonstrated its effectiveness in treating eating disorders and obesity. 75 % of eating disorders patients go into remission in about a year and only 10 % relapse over five years of follow-up.
Mandometer® treatment is more effective than a standard weight loss program. With Mandometer®, the weight loss is maintained, and biological signals for hunger and fullness are re-established.
Mandometer® treatment is a standard treatment in Sweden for eating disorders since 1997. Mandometer® treatment is available in Australia, the United States and Sweden and the 90 people who are employed in the company have brought 1000 eating disorders patients into remission, reducing public spending by some €400 million.
Despite all the technical progress that humans have made, human biology remains the same. We have evolved to work hard for a modest amount of food but today we don´t need to engage in very much physical activity to eat tasteful, high-energy meals because food is too easily available. That is the simple reason why 1,5 billion people are now overweight. To help us deal with today´s un-biological situation, we need external support to control our bodyweight; Mandometer® provides that support.
Our research is carried out in close cooperation with the section for Applied Neuroendocrinology at the Karolinska Institutet.
Professor Per Södersten of the Karolinska Institutet is director of the Mando Group research department and is also one of Mando Group’s founders. He has studied how people eat and what happens to their physiology and emotions when eating patterns change. Since restrictive eating behavior may cause psychological disorders, a patient can change their emotional behavior by learning how to eat normally.
His research is responsible for the development of the Mandometer, the device that facilitates the treatment of patients at our clinics.
You are How you eat
Surprisingly, anorexics and obese share the same problem; to normalize their body weight, they need to learn to recognize normal hunger and fullness. When they have accomplished the task, their body will tell them when to eat and when to stop eating, they will be in control of their food intake and body weight.
Eight treatment resistent adults (6 females, 2 males) in Primary Care with BMI=36 (28-41) kg/m2, were trained during 3 months to eat less, slow down their eating and become more satiated. Four were treated individually and four collectively.
All lost weight, BMI = 34.5 (25.7-40.2) and showed significant clinical improvements. They felt stronger yet did not feel they were dieting.
50 obese adults in 5 Stockholm Primary Care districts are currently treated. They receive 11 visits by an RD, a Mandometer and an Activity Meter.
Ford et al (BMJ 2010) obtained the following results in a randomized controlled trial with Mandometer of obese children and adolescents (11-17 years) over 12 months:
The effect on body weight was maintained six months after treatment.
The results are compelling firstly because an increased speed of eating is the likely cause of obesity and secondly, no one has previously reported an effect on body weight in obese patients persists after non-invasive treatment.
Galhardo et al (JCEM 2012) reported that hormones thought to be engaged in hunger, e.g., ghrelin, and satiety, e.g., peptide tyrosine tyrosine, PYY, can be controlled by eating behavior. Thus the obese children and adolescents reported by Ford et al (2010) were examined at admission and at discharge, 12 months later.
These results show firstly that it is possible to control the hormones associated with eating behavior, reducing the speed of eating brings the hormones under control. Secondly, the results brings into question commonly held assumptions about the cause-effect relationship between hormones and eating behavior. The assumption is that an increase in ghrelin causes eating and that an increase in PYY has the opposite effect. The results reported by Galhardo et al (2012) suggest that it’s the other way around.
Our patients learn how to eat, how much and when to eat based on a proven weight control method. To reinforce healthy eating habits, we use the Mandometer®: an interactive device developed by our research team.
When you restrict the amount of food that you eat, your metabolism slows down to prevent you from starving yourself. When you eventually increase your food intake after a food-restricting diet, your metabolism remains low, and the combination of a low metabolism and an increased amount of food reliably produces a weight gain. In fact, food-restricting dieting will guarantee that you will gain weight.
Obese and anorexics are similarly treated. But while anorexics are encouraged to increase their speed of eating and feel full more slowly, obese patients learn to slow down and feel full more rapidly.
The obese and the overweight are treated as outpatients and they use a Mandometer® at home. When eating too quickly, signals from the stomach fail to reach the brain in time to prevent overeating. Eating with Mandometer® normalizes eating and restores the hormonal balance.
Mandometer® registers the decrease in weight of the plate as you consume food over the course of the meal and compares this with normal weight individuals eating a similar meal.
You will get both visual and audio feedback. At regular intervals, you are also asked to indicate your level of fullness with the guidance of a normal satiety curve.
Training with Mandometer® will help you identify your natural signals for hunger and fullness.
Mando Group AB is a privately owned healthcare company with six clinics in three countries. We treat weight loss and eating disorders with the aid of the patented Mandometer Device.
Mando Group was started by Dr Cecilia Bergh and Professor Per Södersten, after many years of research devoted to understanding eating behavior and satiety at the Karolinska Institutet, Sweden’s foremost medical school.
Cecilia Bergh, PhD
Cecilia Bergh became interested in eating disorders at the beginning of the 1980’s and wrote her doctoral thesis about bulimia. Together with Per Södersten, she has developed the treatment method that is used today at the Mandometer and the Mandolean Clinics. Today Cecilia Bergh is CEO of Mando Group AB.
Per Södersten, Professor
Per Södersten is professor at the Section for Applied Neuroendocrinology at the Karolinska Institutet in Stockholm, Sweden and Director of Research and Development for the Mando Group AB. Through his research, Per Södersten began to understand the special problems that affect people with eating disorders and overweight.
Torbjörn Hultsberg is a business lawyer and a partner at the American law firm Kilpatrick, Townsend & Stockton´s Stockholm office. He has experience from boards both in public and private companies.
Board Member and CEO Mando Group AB
Cecilia Bergh, PhD, one of Mando Group’s founders. She has built up the company together with Per Södersten following many years of research concerning eating behavior and satiety at the Karolinska Institutet. Cecilia Bergh is a board member of the Swedish Entrepreneurship Forum.
Eva Krutmeijer is a senior science communicator and owner of EKKO AB, a consulting company focused on bridging newly acquired knowledge with decision making at different levels for a knowledge-based and sustainable society.
Eva Krutmeijer has an academic background in physical chemistry and has served as head of information at The Royal Swedish Academy of Sciences.
Björn Meister, MD and PhD, is a professor at the Department of Neuroscience, Karolinska Institutet. His research is focused on brain control of food intake and body weight.
Professional board member and an honorary Doctor of tourism research. Former vice president of Ericsson and CEO of SAS. Former Chairman of Karolinska University Hospital.
Jan Stenberg is a lawyer by training.
Per Södersten is one of Mando Group AB’s founders.
He is a professor, head of Section of Applied Neuroendocrinology at the Karolinska Institutet and at the same time Director of R&D at Mando Group AB.